Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 07:21:04 2024-04-23 am EDT 5-day change 1st Jan Change
88.6 EUR +0.49% Intraday chart for Sanofi +2.11% -1.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CAC40: up slightly after encouraging PMI figures CF
Sanofi: positive phase III data in IPT CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations MT
Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team MT
Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer MT
Sanofi Reportedly Agrees to Settle Zantac Cancer Lawsuits for More Than $100 Million MT
SANOFI : Gets a Buy rating from UBS ZD
Sector Update: Health Care Stocks Rise Friday Afternoon MT
Global markets live: P&G, Amex, Blackstone, Apple, Tesla... Our Logo
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Sector Update: Health Care MT
Sanofi Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely MT
Sanofi Reportedly Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely MT
Sanofi to overhaul US operations of vaccines, cut jobs RE
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
SANOFI : JP Morgan reiterates its Neutral rating ZD
Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets MT
BeiGene to Award Shares Worth $15 Million to 11 Directors MT
Sanofi's Frexalimab Reduces Disease Activity in Multiple Sclerosis Patients in Phase 2 Trial MT
Sanofi: new positive phase II results in MS CF
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
88.17 EUR
Average target price
107.5 EUR
Spread / Average Target
+21.92%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Euroapi to Produce Lipids for Sanofi's mRNA Vaccine Platform